Kanazawa University and colleagues have developed a promising new approach to cancer treatment. By using tiny, naturally ...

Researchers develop quinoline-based drug with inhibitory activity against the SARS-CoV-2 papain-like protease (PLpro).

Patients with chronic lymphocytic leukemia (CLL) who experience Richter transformation have a poor prognosis, but ibrutinib ...

Four leading companies CTMC, Iovance Therapeutics, KSQ, and TILT Biotherapeutics prognosticate coming successes of new technology approaches to better tumor-infiltrating lymphocyte activities.

WITH an impressive attendance of 20,522 participants from 131 countries, the European Congress of Radiology (ECR) 2025 was an ...

Australian scientists developed a novel antiviral that targets the SARS-CoV-2 PLpro enzyme, showing strong preclinical ...

Strategic Milestone Achievement and Increased Financial Discipline Underscore Year of Corporate TransformationCompleted enrollment of Part B of Phase 1 glioblastoma study with investigational ...

SINGAPORE and NORTH BRUNSWICK, N.J. and HANGZHOU, China, April 10, 2025 (GLOBE NEWSWIRE) -- Adlai Nortye Ltd. (NASDAQ: ANL) ...

CureVac Announces Financial Results for the Fourth Quarter and Full-Year 2024 and Provides Business Update 10.04.2025 / 13:12 CET/CEST The issuer is solely responsible for the content of this ...